Current Status of Immunotherapies for Treating Pancreatic Cancer

Annie A. Wu; Elizabeth Jaffee; Valerie Lee

doi:10.1007/s11912-019-0811-5

Current Status of Immunotherapies for Treating Pancreatic Cancer

Annie A. Wu, Elizabeth Jaffee, Valerie Lee

School of Medicine

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

Purpose of Review: Despite all efforts, pancreatic ductal adenocarcinoma (PDAC) remains a disease that causes substantial morbidity and mortality, with a 5-year survival rate of 7%. Innovative paradigms for treating PDAC are urgently needed. Recent Findings: We discuss the advances and difficulties in using immunotherapy and developing immunotherapeutic vaccines for PDAC. Current excitement about antigen-specific immunotherapy has been propelled by advances in multiple areas, such as next-generation sequencing to identify neoantigens and manufacturing to produce immunotherapeutic vaccines. Antigen-specific immunotherapy is being actively explored in clinical trials. Summary: As the field of immunotherapy matures and as our understanding of the complex interactions between tumor and host develops, we hope to identify new methods for treating and managing PDAC.

Original language	English (US)
Article number	60
Journal	Current oncology reports
Volume	21
Issue number	7
DOIs	https://doi.org/10.1007/s11912-019-0811-5
State	Published - Jul 1 2019

Keywords

Cancer vaccines
Immunotherapy
Pancreatic adenocarcinoma

ASJC Scopus subject areas

Oncology

Access to Document

10.1007/s11912-019-0811-5

Cite this

@article{808a44677c84409f926ac02373eb2ce4,

title = "Current Status of Immunotherapies for Treating Pancreatic Cancer",

abstract = "Purpose of Review: Despite all efforts, pancreatic ductal adenocarcinoma (PDAC) remains a disease that causes substantial morbidity and mortality, with a 5-year survival rate of 7%. Innovative paradigms for treating PDAC are urgently needed. Recent Findings: We discuss the advances and difficulties in using immunotherapy and developing immunotherapeutic vaccines for PDAC. Current excitement about antigen-specific immunotherapy has been propelled by advances in multiple areas, such as next-generation sequencing to identify neoantigens and manufacturing to produce immunotherapeutic vaccines. Antigen-specific immunotherapy is being actively explored in clinical trials. Summary: As the field of immunotherapy matures and as our understanding of the complex interactions between tumor and host develops, we hope to identify new methods for treating and managing PDAC.",

keywords = "Cancer vaccines, Immunotherapy, Pancreatic adenocarcinoma",

author = "Wu, {Annie A.} and Elizabeth Jaffee and Valerie Lee",

note = "Funding Information: Elizabeth Jaffee has received research funding from Adaptive Biotech, IM Core (Genentech), Lustgarten Foundation, Bristol-Myers Squibb, Breast Cancer Research Foundation, Amgen, and Aduro BioTech; has received travel reimbursement and an honorarium from Adaptive Biotech; has received travel reimbursement and honoraria for participating on scientific advisory boards from Dragonfly Therapeutics, CStone Pharmaceuticals, Genocea Biosciences, Parker Institute, and Lustgarten Foundation; and GVAX and Listeria monocytogenes— Mesothelin are both licensed to Aduro BioTech with the potential to receive royalties. Valerie Lee declares that she has no conflict of interest. Publisher Copyright: {\textcopyright} 2019, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2019",

month = jul,

day = "1",

doi = "10.1007/s11912-019-0811-5",

language = "English (US)",

volume = "21",

journal = "Current oncology reports",

issn = "1523-3790",

publisher = "Current Science, Inc.",

number = "7",

}

TY - JOUR

T1 - Current Status of Immunotherapies for Treating Pancreatic Cancer

AU - Wu, Annie A.

AU - Jaffee, Elizabeth

AU - Lee, Valerie

N1 - Funding Information: Elizabeth Jaffee has received research funding from Adaptive Biotech, IM Core (Genentech), Lustgarten Foundation, Bristol-Myers Squibb, Breast Cancer Research Foundation, Amgen, and Aduro BioTech; has received travel reimbursement and an honorarium from Adaptive Biotech; has received travel reimbursement and honoraria for participating on scientific advisory boards from Dragonfly Therapeutics, CStone Pharmaceuticals, Genocea Biosciences, Parker Institute, and Lustgarten Foundation; and GVAX and Listeria monocytogenes— Mesothelin are both licensed to Aduro BioTech with the potential to receive royalties. Valerie Lee declares that she has no conflict of interest. Publisher Copyright: © 2019, Springer Science+Business Media, LLC, part of Springer Nature.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Purpose of Review: Despite all efforts, pancreatic ductal adenocarcinoma (PDAC) remains a disease that causes substantial morbidity and mortality, with a 5-year survival rate of 7%. Innovative paradigms for treating PDAC are urgently needed. Recent Findings: We discuss the advances and difficulties in using immunotherapy and developing immunotherapeutic vaccines for PDAC. Current excitement about antigen-specific immunotherapy has been propelled by advances in multiple areas, such as next-generation sequencing to identify neoantigens and manufacturing to produce immunotherapeutic vaccines. Antigen-specific immunotherapy is being actively explored in clinical trials. Summary: As the field of immunotherapy matures and as our understanding of the complex interactions between tumor and host develops, we hope to identify new methods for treating and managing PDAC.

AB - Purpose of Review: Despite all efforts, pancreatic ductal adenocarcinoma (PDAC) remains a disease that causes substantial morbidity and mortality, with a 5-year survival rate of 7%. Innovative paradigms for treating PDAC are urgently needed. Recent Findings: We discuss the advances and difficulties in using immunotherapy and developing immunotherapeutic vaccines for PDAC. Current excitement about antigen-specific immunotherapy has been propelled by advances in multiple areas, such as next-generation sequencing to identify neoantigens and manufacturing to produce immunotherapeutic vaccines. Antigen-specific immunotherapy is being actively explored in clinical trials. Summary: As the field of immunotherapy matures and as our understanding of the complex interactions between tumor and host develops, we hope to identify new methods for treating and managing PDAC.

KW - Cancer vaccines

KW - Immunotherapy

KW - Pancreatic adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=85065927428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065927428&partnerID=8YFLogxK

U2 - 10.1007/s11912-019-0811-5

DO - 10.1007/s11912-019-0811-5

M3 - Review article

C2 - 31101991

AN - SCOPUS:85065927428

SN - 1523-3790

VL - 21

JO - Current oncology reports

JF - Current oncology reports

IS - 7

M1 - 60

ER -

Current Status of Immunotherapies for Treating Pancreatic Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this